Editorial Comment on “Tolerability of immune checkpoint inhibitor doublet for advanced renal cell carcinoma patients with pre‐dialysis chronic kidney disease or end‐stage renal disease”
International Journal of Urology · 2023
DOI: 10.1111/iju.15246 ↗At a glance
Editorial in International Journal of Urology, 2023. Written by Shuya Kandori. Institution: Department of Urology, Faculty of Medicine, University of Tsukuba, Tsukuba, Ibaraki, Japan. Major MEDLINE topics: Carcinoma, Renal Cell, Kidney Failure, Chronic, Renal Insufficiency, Chronic, Kidney Neoplasms. 5 references.
Abstract (original language)
CheckMate 214 trial has demonstrated durable clinical benefits of combination therapy with nivolumab plus ipilimumab as a first-line systemic therapy for patients with advanced renal cell carcinoma (aRCC) with an International Metastatic Renal Cell Carcinoma Database Consortium (IMDC) risk score of intermediate or poor risk. Because patients with end-stage renal disease (ESRD) were not included in this trial, clinical data about the efficacy and safety of this therapy for such patients is limited. Immune checkpoint inhibitors (ICIs), such as immunotherapeutic monoclonal antibodies, are metabolized by various routes. First, extensive binding to target antigens in plasma or tissues leads to a reduction in free ICIs. Second, antibodies against ICIs are generated. Third, any remaining ICIs are cleared through proteolytic catabolism, the dominant clearance mechanism. Finally, the high-affinity interaction between ICIs and surface receptors precipitates an additional clearance route through receptor-mediated endocytosis and degradation in target cells. Theoretically, renal function may have little influence on this clearance. Indeed, pharmacokinetics analyses have found no clinically important differences in the clearance of nivolumab or ipilimumab between patients with mild to severe renal impairment and those with normal renal function. Generally, clinicians recognize that these ICIs can be dosed without needing to take renal function into account. In their case series, Bekku et al. show the tolerability of combination therapy with nivolumab plus ipilimumab for mRCC patients with ESRD. As in several other case studies, immune-related adverse event (irAE) profiles in patients with hemodialysis were not significantly different from those in the general population. However, one ESRD patient required hemodialysis initiation due to immune-related pneumonitis and colitis. Therefore, clinicians must be aware of this potential risk in ESRD patients without hemodialysis.
Subjects
MeSH terms (MEDLINE)
Substances
Authors and institutions
- Department of Urology, Faculty of Medicine, University of Tsukuba, Tsukuba, Ibaraki, Japan.
ORCID profiles: Shuya Kandori
Cite
APA
Kandori, S. (2023). Editorial Comment on “Tolerability of immune checkpoint inhibitor doublet for advanced renal cell carcinoma patients with pre‐dialysis chronic kidney disease or end‐stage renal disease”. International Journal of Urology. https://doi.org/10.1111/iju.15246
Vancouver
Kandori S. Editorial Comment on “Tolerability of immune checkpoint inhibitor doublet for advanced renal cell carcinoma patients with pre‐dialysis chronic kidney disease or end‐stage renal disease”. International Journal of Urology. 2023. doi:10.1111/iju.15246
BibTeX
@article{Kandori2023,
author = {Kandori, Shuya},
title = {Editorial Comment on “Tolerability of immune checkpoint inhibitor doublet for advanced renal cell carcinoma patients with pre‐dialysis chronic kidney disease or end‐stage renal disease”},
journal = {International Journal of Urology},
year = {2023},
doi = {10.1111/iju.15246}
}
EUVIMED